@article {Zhoujnumed.121.263674, author = {Quan Zhou and Nynke S. van den Berg and Wenying Kang and Jacqueline Pei and Naoki Nishio and Stan van Keulen and Myrthe A. Engelen and Yu-Jin Lee and Marisa Hom and Johana C. M. Vega Leonel and Zachary Hart and Hannes Vogel and Romain Cayrol and Brock A. Martin and Mark Roesner and Glenn Shields and Natalie Lui and Melanie Hayden Gephart and Roan C. Raymundo and Grace Yi and Monica Granucci and Gerald A. Grant and Gordon Li and Eben L. Rosenthal}, title = {Factors for differential outcome across cancers in clinical molecular-targeted fluorescence imaging}, elocation-id = {jnumed.121.263674}, year = {2022}, doi = {10.2967/jnumed.121.263674}, publisher = {Society of Nuclear Medicine}, abstract = {Clinical imaging performance using a fluorescent antibody was compared across three cancers to elucidate physical and biological factors contributing to differential translation of epidermal growth factor receptor (EGFR) expression to macroscopic fluorescence in tumors. Methods: Thirty-one patients with high-grade glioma (HGG, n = 5), head-and-neck squamous cell carcinoma (HNSCC, n = 23) or lung adenocarcinoma (LAC, n = 3) were systemically infused with 50 mg panitumumab-IRDye800, 1 {\textendash} 3 days prior to surgery. Intraoperative open-field fluorescent images of the surgical field were acquired, where imaging device settings and operating room lighting conditions were tested on tissue-mimicking phantoms. Fluorescence contrast and margin size were measured on resected specimen surface. Antibody distribution and EGFR immunoreactivity were characterized in macroscopic and microscopic histological structures. Integrity of the blood-brain barrier (BBB) was examined via tight junction protein (claudin-5) expression with immunohistochemistry. Stepwise multivariate linear regression of biological variables was performed to identify independent predictors of panitumumab-IRDye800 concentration in tissue. Results: Optimally acquired at the lowest gain for tumor detection with ambient light, intraoperative fluorescence imaging enhanced tissue-size dependent tumor contrast by 5.2-fold, 3.4-fold and 1.4-fold in HGG, HNSCC and LAC, respectively. Tissue surface fluorescence target-to-background ratio correlated with margin size and identified 78 {\textendash} 97\% of at-risk resection margins ex vivo. In 4 {\textmu}m-thick tissue sections, fluorescence detected tumor with 0.85 {\textendash} 0.89 areas under the receiver operating characteristic curves. Preferential breakdown of BBB in HGG improved tumor specificity of intratumoral antibody distribution relative to that of EGFR (96\% vs 80\%) despite its reduced concentration (3.9 ng/mg tissue) compared to HNSCC (8.1 ng/mg) and LAC (6.3 ng/mg). Cellular EGFR expression, tumor cell density, plasma antibody concentration and delivery barrier were independently associated with local intratumoral panitumumab-IRDye800 concentration with 0.62 goodness-of-fit of prediction. Conclusion: In multi-cancer clinical imaging of receptor-ligand based molecular probe, plasma antibody concentration, delivery barrier, as well as intratumoral EGFR expression driven by cellular biomarker expression and tumor cell density, led to heterogeneous intratumoral antibody accumulation and spatial distribution while tumor size, resection margin, and intraoperative imaging settings substantially influenced macroscopic tumor contrast.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/early/2022/03/24/jnumed.121.263674}, eprint = {https://jnm.snmjournals.org/content/early/2022/03/24/jnumed.121.263674.full.pdf}, journal = {Journal of Nuclear Medicine} }